ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 9.190-9.690 for the period, compared to the consensus earnings per share estimate of 9.100. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ANIP. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Guggenheim restated a “buy” rating and issued a $124.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Canaccord Genuity Group began coverage on ANI Pharmaceuticals in a research note on Thursday, July 16th. They issued a “hold” rating and a $91.00 price target on the stock. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $105.00.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $82.63 on Friday. The company has a market cap of $1.88 billion, a P/E ratio of 20.92 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The stock has a 50-day moving average of $81.03 and a two-hundred day moving average of $79.38. ANI Pharmaceuticals has a 1-year low of $67.98 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.70 earnings per share. As a group, analysts anticipate that ANI Pharmaceuticals will post 8.03 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Ori Gutwerg sold 2,772 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $79.50, for a total value of $220,374.00. Following the sale, the senior vice president directly owned 78,696 shares in the company, valued at approximately $6,256,332. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Patrick D. Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the transaction, the director owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. This trade represents a 20.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 88,029 shares of company stock valued at $6,954,472. 8.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Maryland State Retirement & Pension System grew its holdings in ANI Pharmaceuticals by 5.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after purchasing an additional 134 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its stake in shares of ANI Pharmaceuticals by 1.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after buying an additional 198 shares during the last quarter. Federation des caisses Desjardins du Quebec raised its stake in shares of ANI Pharmaceuticals by 0.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock worth $3,110,000 after buying an additional 221 shares during the last quarter. Amundi boosted its position in shares of ANI Pharmaceuticals by 1.2% in the 3rd quarter. Amundi now owns 23,918 shares of the specialty pharmaceutical company’s stock worth $2,202,000 after buying an additional 285 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of ANI Pharmaceuticals by 1.5% in the 3rd quarter. Alliancebernstein L.P. now owns 20,310 shares of the specialty pharmaceutical company’s stock worth $1,860,000 after buying an additional 300 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.